dc.relation.reference | 1. Ullrich V, Nusing R. Thromboxane synthase. From isolation to function. Stroke. 1990; 21: 134-138.
2. Tanabe T, Ullrich V. Prostacyclin and thromboxane synthases. J Lipid Mediat Cell Signal. 1995; 12: 243-255.
3. Ruan KH, Wang LH, Wu KK, Kulmacz RJ. Amino-terminal topology of thromboxane synthase in the endoplasmic reticulum. J Biol Chem. 1993; 268:19483-19490.
4. Ogletree ML. Overview of physiological and pathophysiological effects of thromboxane A2. Fed Proc. 1987; 46: 133-138.
5. Patrono C. Biosynthesis and pharmacological modulation of thromboxane in humans. Circulation. 1990; 81: I12-15; discussion I22-13.
6. Lages B, Malmsten C, Weiss HJ, Samuelsson B. Impaired platelet response to thromboxane-A2 and defective calcium mobilization in a patient with a bleeding disorder. Blood. 1981; 57: 545-552.
7. Samama M, Lecrubier C, Conard J, Hotchen M, Breton-Gorius J, Vargaftig B, Chignard M, Lagarde M, Dechavanne M. Constitutional thrombocytopathy with subnormal response to thromboxane A2. Br J Haematol. 1981; 48: 293-303.
8. Wu KK, Le Breton GC, Tai HH, Chen YC. Abnormal platelet response to thromboxane A2. J Clin Invest. 1981; 67: 1801-1804.
9. Wu KK, Minkoff IM, Rossi EC, Chen YC. Hereditary bleeding disorder due to a primary defect in platelet release reaction. Br J Haematol. 1981; 47: 241-249.
10. Mestel F, Oetliker O, Beck E, Felix R, Imbach P, Wagner HP. Severe bleeding associated with defective thromboxane synthetase. Lancet. 1980; 1: 157.
11. Weiss HJ, Lages BA. Possible congenital defect in platelet thromboxane synthetase. Lancet. 1977; 1: 760-761.
12. Hirata T, Kakizuka A, Ushikubi F, Fuse I, Okuma M, Narumiya S. Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J Clin Invest. 1994; 94: 1662-1667.
13. Ali S, Davis MG, Becker MW, Dorn GW, 2nd. Thromboxane A2 stimulates vascular smooth muscle hypertrophy by up- regulating the synthesis and release of endogenous basic fibroblast growth factor. J Biol Chem. 1993; 268: 17397-17403.
14. Hanasaki K, Nakano T, Arita H. Receptor-mediated mitogenic effect of thromboxane A2 in vascular smooth muscle cells. Biochem Pharmacol. 1990; 40: 2535-2542.
15. Baylis C. Effects of administered thromboxanes on the intact, normal rat kidney. Ren Physiol. 1987; 10: 110-121
16. Mene P, Dunn MJ. Contractile effects of TxA2 and endoperoxide analogues on cultured rat glomerular mesangial cells. Am J Physiol. 1986; 251: F1029-1035.
17. Wilcox CS, Welch WJ, Snellen H. Thromboxane mediates renal hemodynamic response to infused angiotensin II. Kidney Int. 1991; 40: 1090-1097.
18. Welch WJ, Wilcox CS. Potentiation of tubuloglomerular feedback in the rat by thromboxane mimetic. Role of macula densa. J Clin Invest. 1992; 89: 1857-1865.
19. Burch RM, Halushka PV. Vasopressin stimulates prostaglandin and thromboxane synthesis in toad bladder epithelial cells. Am J Physiol. 1982; 243: F593-597.
20. Donadio JV, Jr., Anderson CF, Mitchell JC, 3rd, Holley KE, Ilstrup DM, Fuster V, Chesebro JH. Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy. N Engl J Med. 1984; 310: 1421-1426.
21. FitzGerald GA, Healy C, Daugherty J. Thromboxane A2 biosynthesis in human disease. Fed Proc. 1987; 46: 154-158.
22. Craven PA, Melhem MF, DeRubertis FR. Thromboxane in the pathogenesis of glomerular injury in diabetes. Kidney Int. 1992; 42: 937-946.
23. DeRubertis FR, Craven PA. Eicosanoids in the pathogenesis of the functional and structural alterations of the kidney in diabetes. Am J Kidney Dis. 1993; 22: 727-735.
24. Endoh M, Kashem A, Yamauchi F, Yano N, Nomoto Y, Sakai H, Kurokawa K. Expression of thromboxane synthase in kidney tissues from patients with IgA nephropathy. Clin Nephrol. 1997; 47: 168-175.
25. Ushikubi F, Aiba Y, Nakamura K, Namba T, Hirata M, Mazda O, Katsura Y, Narumiya S. Thromboxane A2 receptor is highly expressed in mouse immature thymocytes and mediates DNA fragmentation and apoptosis. J Exp Med. 1993; 178: 1825-1830.
26. Ruiz P, Rey L, Spurney R, Coffman T, Viciana A. Thromboxane augmentation of alloreactive T cell function. Transplantation. 1992; 54: 498-505.
27. Ceuppens JL, Vertessen S, Deckmyn H, Vermylen J. Effects of thromboxane A2 on lymphocyte proliferation. Cell Immunol. 1985; 90: 458-463.
28. Farrukh IS, Michael JR, Summer WR, Adkinson NF, Jr., Gurtner GH. Thromboxane-induced pulmonary vasoconstriction: involvement of calcium. J Appl Physiol. 1985; 58: 34-44.
29. Fitzgerald DJ, Rocki W, Murray R, Mayo G, FitzGerald GA. Thromboxane A2 synthesis in pregnancy-induced hypertension. Lancet. 1990; 335: 751-754.
30. Hsu CY, Halushka PV, Hogan EL, Banik NL, Lee WA, Perot PL, Jr. Alteration of thromboxane and prostacyclin levels in experimental spinal cord injury. Neurology. 1985; 35: 1003-1009.
31. Chen ST, Hsu CY, Hogan EL, Halushka PV, Linet OI, Yatsu FM. Thromboxane, prostacyclin, and leukotrienes in cerebral ischemia. Neurology. 1986;36: 466-470.
32. Whittle BJ, Kauffman GL, Moncada S. Vasoconstriction with thromboxane A2 induces ulceration of the gastric mucosa. Nature. 1981; 292: 472-474.
33. Needleman P, Moncada S, Bunting S, Vane JR, Hamberg M, Samuelsson B. Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature. 1976; 261: 558-560.
34. Sun FF, Chapman JP, McGuire JC. Metabolism of prostaglandin endoperoxide in animal tissues. Prostaglandins. 1977; 14: 1055-1074
35. Haurand M, Ullrich V. Isolation and characterization of thromboxane synthase from human platelets as a cytochrome P-450 enzyme. J Biol Chem. 1985; 260: 15059-15067.
36. Shen RF, Tai HH. Immunoaffinity purification and characterization of thromboxane synthase from porcine lung. J Biol Chem. 1986; 261: 11592-11599.
37. Needleman P, Minkes M, Raz A. Thromboxanes: selective biosynthesis and distinct biological properties. Science. 1976; 193: 163-165.
38. Diczfalusy U, Falardeau P, Hammarstrom S. Conversion of prostaglandin endoperoxides to C17-hydroxy acids catalyzed by human platelet thromboxane synthase. FEBS Lett. 1977; 84: 271-274.
39. Hecker M, Ullrich V. On the mechanism of prostacyclin and thromboxane A2 biosynthesis. J Biol Chem. 1989; 264: 141-150.
40. Liu Y, Yoden K, Shen RF, Tai HH. 12-L-hydroxy-5,8,10-heptadecatrienoic acid (HHT) is an excellent substrate for NAD+-dependent 15-hydroxyprostaglandin dehydrogenase. Biochem Biophys Res Commun. 1985; 129: 268-274.
41. Chaudhary AK, Nokubo M, Reddy GR, Yeola SN, Morrow JD, Blair IA, Marnett LJ. Detection of endogenous malondialdehyde-deoxyguanosine adducts in human liver. Science. 1994; 265: 1580-1582.
42. Jones DA, Fitzpatrick FA. Thromboxane A2 synthase. Modification during "suicide" inactivation. J Biol Chem. 1991; 266: 23510-23514.
43. Ohashi K, Ruan KH, Kulmacz RJ, Wu KK, Wang LH. Primary structure of human thromboxane synthase determined from the cDNA sequence. J Biol Chem. 1992; 267: 789-793.
44. Yokoyama C, Miyata A, Ihara H, Ullrich V, Tanabe T. Molecular cloning of human platelet thromboxane A synthase. Biochem Biophys Res Commun. 1991; 178: 1479-1484.
45. Zhang L, Chase MB, Shen RF. Molecular cloning and expression of murine thromboxane synthase. Biochem Biophys Res Commun. 1993; 194: 741-748.
46. Shen RF, Zhang L, Baek SJ, Tai HH, Lee KD. The porcine thromboxane synthase-encoding cDNA: sequence, mRNA expression and enzyme production in Sf9 insect cells. Gene. 1994; 140: 261-265.
47. Tone Y, Miyata A, Hara S, Yukawa S, Tanabe T. Abundant expression of thromboxane synthase in rat macrophages. FEBS Lett. 1994; 340: 241-244.
48. Wang LH, Ohashi K, Wu KK. Isolation of partial complementary DNA encoding human thromboxane synthase. Biochem Biophys Res Commun. 1991; 177: 286-291.
49. Ruan KH, Li P, Kulmacz RJ, Wu KK. Characterization of the structure and membrane interaction of NH2- terminal domain of thromboxane A2 synthase. J Biol Chem. 1994; 269: 20938-20942.
50. Xia Z, Tai HH. Bacterial expression of functional membrane-bound thromboxane synthase having intact sequence and truncated N-terminal hydrophobic segment. Arch Biochem Biophys. 1995; 321: 531-534.
51. Ruan KH, Milfeld K, Kulmacz RJ, Wu KK. Comparison of the construction of a 3-D model for human thromboxane synthase using P450cam and BM-3 as templates: implications for the substrate binding pocket. Protein Eng. 1994; 7: 1345-1351.
52. Wang LH, Matijevic-Aleksic N, Hsu PY, Ruan KH, Wu KK, Kulmacz RJ. Identification of thromboxane A2 synthase active site residues by molecular modeling-guided site-directed mutagenesis. J Biol Chem. 1996; 271: 19970-19975.
53. Xia Z, Shen RF, Baek SJ, Tai HH. Expression of two different forms of cDNA for thromboxane synthase in insect cells and site-directed mutagenesis of a critical cysteine residue. Biochem J. 1993; 295: 457-461.
54. Zhang L, Xiao H, Schultz RA, Shen RF. Genomic organization, chromosomal localization, and expression of the murine thromboxane synthase gene. Genomics. 1997; 45: 519-528.
55. Miyata A, Yokoyama C, Ihara H, Bandoh S, Takeda O, Takahashi E, Tanabe T. Characterization of the human gene (TBXAS1) encoding thromboxane synthase. Eur J Biochem. 1994; 224: 273-279.
56. Baek SJ, Lee KD, Shen RF. Genomic structure and polymorphism of the human thromboxane synthase- encoding gene. Gene. 1996; 173: 251-256.
57. Harada N, Yamada K, Saito K, Kibe N, Dohmae S, Takagi Y. Structural characterization of the human estrogen synthetase (aromatase) gene. Biochem Biophys Res Commun. 1990; 166: 365-372.
58. Hashimoto H, Toide K, Kitamura R, Fujita M, Tagawa S, Itoh S, Kamataki T. Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur J Biochem. 1993; 218: 585-595.
59. Nebert DW, Gonzalez FJ. P450 genes: structure, evolution, and regulation. Annu Rev Biochem. 1987; 56: 945-993
60. Nebert DW, Nelson DR, Coon MJ, Estabrook RW, Feyereisen R, Fujii-Kuriyama Y, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF, et al. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol. 1991; 10: 1-14.
61. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 1996; 6: 1-42.
62. Sinzinger H, O'Grady J, Demers LM, Granstrom E, Kumlin M, Nell A, Peskar BA, Salmon JA, Westlund P. Thromboxane in cardiovascular disease. Eicosanoids. 1990; 3: 59-64
63. Tazawa R, Green ED, Ohashi K, Wu KK, Wang LH. Characterization of the complete genomic structure of human thromboxane synthase gene and functional analysis of its promoter. Arch Biochem Biophys. 1996; 334: 349-356.
64. Shen RF, Tai HH. Monoclonal antibodies to thromboxane synthase from porcine lung. Production and application to development of a tandem immunoradiometric assay. J Biol Chem. 1986; 261: 11585-11591.
65. Nusing R, Sauter G, Fehr P, Durmuller U, Kasper M, Gudat F, Ullrich V. Localization of thromboxane synthase in human tissues by monoclonal antibody Tu 300. Virchows Arch A Pathol Anat Histopathol. 1992; 421: 249-254
66. Woodworth SH, Li X, Lei ZM, Rao CV, Yussman MA, Spinnato JA, 2nd, Yokoyama C, Tanabe T, Ullrich V. Eicosanoid biosynthetic enzymes in placental and decidual tissues from preeclamptic pregnancies: increased expression of thromboxane-A2 synthase gene. J Clin Endocrinol Metab. 1994; 78: 1225-1231.
67. Takahashi N, Takeuchi K, Abe T, Murakami K, Yamaguchi M, Abe K. Immunohistochemical localization of thromboxane receptor and thromboxane synthase in rat testis. Endocrinology. 1995; 136: 4143-4146.
68. Lee KD, Baek SJ, Shen RF. Cloning and characterization of the human thromboxane synthase gene promoter. Biochem Biophys Res Commun. 1994; 201: 379-387.
69. Wang LH, Tazawa R, Lang AQ, Wu KK. Alternate splicing of human thromboxane synthase mRNA. Arch Biochem Biophys. 1994; 315: 273-278.
70. Ingerman-Wojenski C, Silver MJ, Smith JB, Macarak E. Bovine endothelial cells in culture produce thromboxane as well as prostacyclin. J Clin Invest. 1981; 67: 1292-1296.
71. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev. 1994; 46: 205-229.
72. Hirata M, Hayashi Y, Ushikubi F, Yokota Y, Kageyama R, Nakanishi S, Narumiya S. Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature. 1991; 349: 617-620.
73. Namba T, Sugimoto Y, Hirata M, Hayashi Y, Honda A, Watabe A, Negishi M, Ichikawa A, Narumiya S. Mouse thromboxane A2 receptor: cDNA cloning, expression and northern blot analysis. Biochem Biophys Res Commun. 1992; 184: 1197-1203.
74. Baldassare JJ, Tarver AP, Henderson PA, Mackin WM, Sahagan B, Fisher GJ. Reconstitution of thromboxane A2 receptor-stimulated phosphoinositide hydrolysis in isolated platelet membranes: involvement of phosphoinositide-specific phospholipase C-beta and GTP-binding protein Gq. Biochem J. 1993; 291: 235-240.
75. Arita H, Nakano T, Hanasaki K. Thromboxane A2: its generation and role in platelet activation. Prog Lipid Res. 1989; 28: 273-301.
76. Dorn GW 2nd, Becker MW. Thromboxane A2 stimulated signal transduction in vascular smooth muscle. J Pharmacol Exp Ther. 1993; 265: 447-456.
77. Morinelli TA, Zhang LM, Newman WH, Meier KE. Thromboxane A2/prostaglandin H2-stimulated mitogenesis of coronary artery smooth muscle cells involves activation of mitogen-activated protein kinase and S6 kinase. J Biol Chem. 1994; 269: 5693-5698.
78. Thomas DW, Mannon RB, Mannon PJ, Latour A, Oliver JA, Hoffman M, Smithies O, Koller BH, Coffman TM. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. J Clin Invest. 1998; 102: 1994-2001.
79. van der Lugt N, Maandag ER, te Riele H, Laird PW, Berns A. A pgk:hprt fusion as a selectable marker for targeting of genes in mouse embryonic stem cells: disruption of the T-cell receptor delta- chain-encoding gene. Gene. 1991; 105: 263-267.
80. Tybulewicz VL, Crawford CE, Jackson PK, Bronson RT, Mulligan RC. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell. 1991; 65: 1153-1163.
81. Hooper M, Hardy K, Handyside A, Hunter S, Monk M. HPRT-deficient (Lesch-Nyhan) mouse embryos derived from germline colonization by cultured cells. Nature. 1987; 326: 292-294.
82. Colucci-Guyon E, Portier MM, Dunia I, Paulin D, Pournin S, Babinet C. Mice lacking vimentin develop and reproduce without an obvious phenotype. Cell. 1994; 79: 679-694.
83. Yu IS, Chen HJ, Lee YS, et al. Mice deficient in hepsin, a serine protease, exhibit normal embryogenesis and unchanged hepatocyte regeneration ability. Thromb. Haemost. 2000; 84: 865-870.
84. Ramirez-Solis R, Davis AC, Bradley A. Gene targeting in embryonic stem cells. Methods Enzymol. 1993; 225: 855-878.
85. Lin SR, Yu IS, Huang PH, Tsai CW, Lin SW. Chimeric mice with disruption of the gene coding for phosphatidylinositol glycan class A (Pig-a) were defective in embryogenesis and spermatogenesis. Br. J. Haematol. 2000; 110: 682-693.
86. Stenberg PE, Barrie RJ, Pestina TI, et al. Prolonged bleeding time with defective platelet filopodia formation in the Wistar Furth rat. Blood. 1998; 91: 1599-1605.
87. Dejana E, Callioni A, Quintana A, de Gaetano G. Bleeding time in laboratory animals. II - A comparison of different assay conditions in rats. Thromb. Res. 1979; 15: 191-197.
88. Matsuda H, Ushio H, Geba GP, Askenase PW. Human platelets can initiate T cell-dependent contact sensitivity through local serotonin release mediated by IgE antibodies. J. Immunol. 1997; 158: 2891-2897.
89. Defreyn G, Machin SJ, Carreras LO, Dauden MV, Chamone DAF, Vermylen J. Familial bleeding tendency with partial platelet thromboxane synthetase deficiency: reorientation of cyclic endoperoxide metabolism. Brit. J Haematol. 1981; 49: 29-41.
90. Deveaux, S., Cohen-Kaminsky, S., Shivdasani, R.A., Andrews, N.C., Filipe, A., Kuzniak, I., Orkin, S.H., Romeo, P.H., and Mignotte, V. p45 NF-E2 regulates expression of thromboxane synthase in megakaryocytes. EMBO J. 1997; 16: 5654-5661.
91. Shivdasani, R.A., Rosenblatt, M.F., Zucker-Franklin, D., Jackson, C.W., Hunt, P., Saris, C.J.M., and Orkin, S.H. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell 1995; 81: 695-704.
92. Vezza, R., Mezzasoma, A. M., Venditti, G., and Gresele, P. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets. Thromb. Haemost. 2002; 87: 114-121.
93. Myers, A.K., and Ramwell, P.W. Thromboxane in sudden death. Adv. Prostaglandin Thromboxane Leukot. Res. 1985; 13: 81-88.
94. Torres Duarte, A.P., Ramwell, P., and Myers, A. Sex differences in mouse platelet aggregation. Thromb Res. 1986; 43: 33-39.
95. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol. 1997; 17: 2309-2315.
96. Pratico D, Tangirala RK, Rader DJ, Rokach J, FitzGerald GA. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat Med. 1998; 4: 1189-1192.
97. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001; 294: 1871-1875.
98. Zhao L, Funk CD. Lipoxygenase pathways in atherogenesis. Trends Cardiovasc Med. 2004; 14: 191-195.
99. Sendobry SM, Cornicelli JA, Welch K, Bocan T, Tait B, Trivedi BK, Colbry N, Dyer RD, Feinmark SJ, Daugherty A. Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties. Br J Pharmacol. 1997; 120: 1199-1206.
100. Bocan TM, Rosebury WS, Mueller SB, Kuchera S, Welch K, Daugherty A, Cornicelli JA. A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit. Atherosclerosis. 1998; 136: 203-16.
101. Aiello RJ, Bourassa PA, Lindsey S, Weng W, Freeman A, Showell HJ. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol. 2002; 22: 443-449.
102. Subbarao K, Jala VR, Mathis S, Suttles J, Zacharias W, Ahamed J, Ali H, Tseng MT, Haribabu B. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol. 2004; 24: 369-375.
103. Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF, Funk CD. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest. 1999; 103: 1597-1604.
104. George J, Afek A, Shaish A, Levkovitz H, Bloom N, Cyrus T, Zhao L, Funk CD, Sigal E, Harats D. 12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice. Circulation. 2001; 104: 1646-1650.
105. Zhao L, Cuff CA, Moss E, Wille U, Cyrus T, Klein EA, Pratico D, Rader DJ, Hunter CA, Pure E, Funk CD. Selective interleukin-12 synthesis defect in 12/15-lipoxygenase-deficient macrophages associated with reduced atherosclerosis in a mouse model of familial hypercholesterolemia. J Biol Chem. 2002; 277: 35350-35356.
106. Mehrabian M, Allayee H, Wong J, Shi W, Wang XP, Shaposhnik Z, Funk CD, Lusis AJ. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res. 2002; 91: 120-126.
107. Loftin, C.D., Trivedi, D.B., Tiano, H.F., Clark, J.A., Lee, C.A., Epstein, J.A., Morham, S.G., Breyer, M.D., Nguyen, M., Hawkins, B.M., et al. Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2. Proc. Natl. Acad. Sci. U. S. A. 2001; 98: 1059-1064.
108. Nguyen, M., Camenisch, T., Snouwaert, J.N., Hicks, E., Coffman, T.M., Anderson, P.A., Malouf, N.N., and Koller, B.H. The prostaglandin receptor EP4 triggers remodeling of the cardiovascular system at birth. Nature 1997; 390: 78-81.
109. Segi, E., Sugimoto, Y., Yamasaki, A., Aze, Y., Oida, H., Nishimura, T., Murata, T., Matsuoka, T., Ushikubi, F., Hirose, M., et al. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. Biochem. Biophys. Res. Commun. 1998; 246: 7-12.
110. Loftin, C.D., Trivedi, D.B., and Langenbach, R. Cyclooxygenase-1-selective inhibition prolongs gestation in mice without adverse effects on the ductus arteriosus. J. Clin. Invest. 2002; 110: 549-557.
111. Verstraete, M., and Zoldhelyi, P. Novel antithrombotic drugs in development. Drugs 1995; 49: 856-884.
112. De Clerck, F., Beetens, J., Van de Water, A., Vercammen, E., and Janssen, P.A. R68070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo. Thromb. Haemost. 1989; 61: 43-49.
113. Patrono, C. Biosynthesis and pharmacological modulation of thromboxane in humans. Circulation 1990; 81 (1 suppl 1): I12-I15.
114. Berrettini, M., De Cunto, M., Parise, P., Grasselli, S., and Nenci, G.G. "In vitro" and "ex vivo" effects of picotamide, a combined thromboxane A2-synthase inhibitor and -receptor antagonist, on human platelets. Eur. J. Clin. Pharmacol. 1990; 39: 495-500.
. | en |